Oramed to Announce Results of its Phase 2a Clinical Trial for Oral Insulin on January 30th at the Tel Aviv Stock Exchange

Oramed to Announce Results of its Phase 2a Clinical Trial for Oral Insulin on
                 January 30th at the Tel Aviv Stock Exchange

PR Newswire

JERUSALEM, January 27, 2014

JERUSALEM, January 27, 2014 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a
developer of oral drug delivery systems, announced today that it will announce
the results of its Phase 2a clinical trial for the company's ORMD-0801 oral
insulin capsule for the treatment of type 2 diabetes on January 30, 2014.
Oramed CEO Nadav Kidron will present the findings at an investor conference
taking place at the Tel Aviv Stock Exchange in Tel Aviv, Israel.

The Phase 2a trial was conducted in the U.S. under the auspices of the FDA and
was designed to show the drug's overall safety profile. Thirty patients with
type 2 diabetes took part in the double-blind, randomized trial in an
in-patient setting for one week of treatment.

About ORMD-0801 Oral Insulin

Oramed's ORMD-0801 is an orally ingestible insulin capsule for the early
stages of type 2 diabetes, when it can still slow the rate of degeneration of
the disease by providing additional insulin to the body and allowing
pancreatic respite. Moreover, orally administered insulin has the potential
benefit of enhanced patient compliance at this crucial stage as well as the
advantage of mimicking insulin's natural location and gradients in the body by
first passing through the liver before entering the bloodstream. For more
information on ORMD-0801, the content of which is not part of this press
release, please visit: http://oramed.com/index.php?page=14

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery
solutions for drugs and vaccines currently delivered via injection.
Established in 2006, Oramed's Protein Oral Delivery (POD^TM) technology is
based on over 30 years of research by top research scientists at Jerusalem's
Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of
diabetes through its proprietary flagship product, an orally ingestible
insulin capsule (ORMD-0801) currently in Phase 2 clinical trials on patients
with type 2 diabetes (T2DM) under an Investigational New Drug application with
the U.S. Food and Drug Administration, and with its oral exenatide capsule
(ORMD-0901; a GLP-1 analog) currently scheduled to start IND-enabling trials.
Oramed is also moving forward with clinical trials of ORMD-0801 for the
treatment of type 1 diabetes (T1DM). The company's corporate and R&D
headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release,
please visithttp://www.oramed.com

Forward-looking statements:This press release contains forward-looking
statements. For example, we are using forward-looking statements when we
discuss the expected timing forannouncement of our Phase2a clinical trial,
when we discuss the potential benefits of orally administered insulin, when we
discuss our clinical trials or revolutionizing the treatment of diabetes with
our products.These forward-looking statements and their implications are
based on the current expectations of the management of Oramed only, and are
subject to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval or patent protection
for our product candidates; competition from other pharmaceutical or
biotechnology companies; and our ability to obtain additional funding required
to conduct our research, development and commercialization activities. In
addition, the following factors, among others, could cause actual results to
differ materially from those described in the forward-looking statements:
changes in technology and market requirements; delays or obstacles in
launching our clinical trials; changes in legislation; inability to timely
develop and introduce new technologies, products and applications; lack of
validation of our technology as we progress further and lack of acceptance of
our methods by the scientific community; inability to retain or attract key
employees whose knowledge is essential to the development of our products;
unforeseen scientific difficulties that may develop with our process; greater
cost of final product than anticipated; loss of market share and pressure on
pricing resulting from competition; laboratory results that do not translate
to equally good results in real settings; our patents may not be sufficient;
and final that products may harm recipients, all of which could cause the
actual results or performance of Oramed to differ materially from those
contemplated in such forward-looking statements. Except as otherwise required
by law, Oramed undertakes no obligation to publicly release any revisions to
these forward-looking statements to reflect events or circumstances after the
date hereof or to reflect the occurrence of unanticipated events. For a more
detailed description of the risks and uncertainties affecting Oramed,
reference is made to Oramed's reports filed from time to time with the
Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Office: +972-2-566-0001
US: +1-718-831-2512
Email: aviva@oramed.com

SOURCE Oramed Pharmaceuticals Inc.
Press spacebar to pause and continue. Press esc to stop.